会上，医渡科技生命科学临床试验业务副总裁刘颖表示，多年来，医渡科技凭借积累的医疗大数据处理 能力、疾病理解能力与疾病知识图谱构建优势，依托自主研发的"AI医疗大脑"YiduCore，构建起覆盖临 床试验全流程的智能临床研究一体化解决方案。该解决方案在临床试验方案优化、患者智能招募、临床 运营等药物研发关键环节大幅提速超30%，有效推动研发效率提升、产品上市路径优化及创新成本降 低。 智通财经APP获悉，医渡科技(02158)尾盘涨超5%，截至发稿，涨5.24%，报6.43港元，成交额3658.84万 港元。 消息面上，据IT新闻网报道，近日，由中国食品药品企业质量安全促进会指导，同写意主办的"T20+大 会"在苏州召开，大会聚焦新药研发全链条创新，破解产业升级关键命题。国内AI医疗头部企业医渡科 技携智能临床研究一体化解决方案亮相大会，系统呈现了AI驱动临床研究效率提升的可复制路径。据 悉，目前医渡科技已服务超过350家国内外制药企业，积累了686个临床试验项目经验，前瞻性及回顾性 真实世界研究项目达275项。 ...

Group 1 - The core viewpoint of the articles highlights the strong performance of AI healthcare and smart medical indices in the Hong Kong stock market, with the Hong Kong medical ETF (159366) rising by 2.58% and achieving a trading volume exceeding 300 million RMB, indicating active market participation [1] - JD Health reported a significant increase in its mid-year performance for 2025, with total revenue reaching 35.3 billion RMB, a year-on-year growth of 24.5%, and a Non-IFRS net profit of 3.57 billion RMB, up 35% [1] - Over the past three months, the Hong Kong medical ETF (159366) has seen a remarkable increase of over 37% in its adjusted net asset value [1] Group 2 - The National Development and Reform Commission has approved the establishment of a "National AI Application Pilot Base" in the medical field, led by Zhongshan Hospital affiliated with Fudan University, focusing on clinical research and addressing industry pain points [2] - AI healthcare is expected to shift the diagnostic and treatment paradigm from an "experience-driven" model to a "data-driven" model, despite current challenges such as data barriers [2] - The Hong Kong medical ETF (159366) includes a selection of 50 listed companies in the medical field, reflecting the overall performance of the sector within the Hong Kong Stock Connect [2] Group 3 - As of June 30, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Medical Theme Index (932069) include WuXi Biologics, JD Health, WuXi AppTec, Alibaba Health, Sinopharm, Kingstar Bio, Weigao Group, China Biologic Products, CanSino Biologics, and MicroPort Scientific, collectively accounting for 56.9% of the index [3]

Core Viewpoint - The recent announcement by Crystal Tech Holdings regarding a collaboration with DoveTree has created significant excitement in the capital market, marking a breakthrough in the commercialization of AI in healthcare [2] Market Dynamics - The AI healthcare sector is experiencing explosive growth, driven by supportive policies and increasing capital investment [4] - The Chinese AI healthcare market is projected to grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate of 43.1% [5] - The average financing amount in the AI healthcare sector has increased significantly, from 80 million yuan in 2019 to 320 million yuan in 2024 [5] Policy Support - The Chinese government has implemented a series of policies to promote the integration of AI in healthcare, including the "Artificial Intelligence +" initiative [4] - Local governments are also providing financial support for AI healthcare projects, with significant funding allocated to pilot programs [4] Challenges in the Industry - Despite the enthusiasm, the industry faces challenges such as data barriers, clinical validation, and commercialization pathways [3] - Regulatory scrutiny remains stringent, with no relaxation of IPO standards for AI healthcare companies [6] - Issues related to revenue recognition and the commercial viability of AI solutions are critical for companies seeking to go public [6] Investment Landscape - The investment community is increasingly focused on the efficiency and cost optimization potential of AI applications in healthcare [7] - Companies are exploring international markets, but face significant regulatory hurdles in the U.S. healthcare system [7][9] Sector Differentiation - There is a growing divergence within the AI healthcare sector, with emerging profitable cases in niche areas such as surgical robotics and intelligent supply management [8] - The market may favor companies that can establish service barriers and address clinical pain points without overly relying on insurance payments [9]

Group 1 - The core viewpoint of the articles highlights the recent approval of an unprofitable biopharmaceutical company for IPO under the fifth listing standard of the Sci-Tech Innovation Board, signaling a positive shift in the financing environment for similar companies [1] - The fifth listing standard, which had previously faced a "zero acceptance" situation, is now being revitalized, indicating a renewed confidence from regulators in the long-term value of hard technology [1] - There are currently four other similar companies awaiting review for IPO under the same standard, suggesting a potential increase in market activity for unprofitable biopharmaceutical firms [1] Group 2 - The Sci-Tech Innovation Board's biopharmaceutical ETF (588860) has shown active trading, with an average daily trading volume of 31.1566 million yuan as of August 14, indicating strong investor interest [1][2] - The ETF tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in the biopharmaceutical sector, reflecting the overall performance of this industry [2] - The top three weighted industries within the index are chemical pharmaceuticals (39.7%), medical devices (33%), and biological products (18.7%), highlighting the sector's composition [2] Group 3 - The innovation drug sector is expected to maintain its growth momentum, driven by policy support, increasing global competitiveness, and the realization of commercial profitability [3] - There is an anticipated recovery in demand for the domestic market by 2025, particularly in the consumer healthcare sector, which includes medical services and traditional Chinese medicine [3] - The medical device sector is also projected to see improvements by 2025, indicating a broader recovery trend within the healthcare industry [3]

截至10时37分，济民健康涨幅为10.00%，已连续2个交易日涨停。最新价8.91元，总市值46.79亿元，封 板资金0.07亿元，成交额7.43亿元，换手率16.51%。 根据分析，可能的影响因素如下： 济民健康主要涉及生物技术、人工智能、医疗器械、医疗服务、增持回购等概念板块。 注：本内容由算法自动生成，不构成投资建议。 来源：金融界 1. 与达博生物在细胞基因治疗领域开展战略合作，布局溶瘤病毒药物研发，关联医疗健康行业中的生物 技术题材。 2. 参与人工智能创业发展基金，切入AI+医疗科技领域，关联人工智能与医疗融合题材。 3. 推出1-2亿元股份回购计划，强化市场信心，关联增持回购概念。 ...

8月15日早盘，港股互联网医疗股持续拉升，京东健康涨超13%，平安好医生涨近10%，阿里健康涨近 7%。重仓京东健康、阿里健康等AI医疗龙头企业的港股通医疗ETF（520510）盘中现涨超2%，板块情 绪持续冲高。 消息面上，京东健康发布截至2025年6月30日止6个月的中期业绩，该集团取得收入人民币352.9亿元， 同比增加24.5%；期间非国际财务报告准则盈利35.7亿元，同比增加35%。超预期的业绩表现显著提振 市场信心，也为AI医疗板块注入一剂强心针。作为AI医疗与互联网药店的龙头，京东健康已构建起覆 盖医、检、诊、药的服务闭环，持续升级并推出全场景AI医疗产品，凭借高效透明的AI互联网药店及 AI京医系列产品，精准满足患者与医生的多层次、个性化需求。同时，京东健康持续布局全渠道医疗 服务能力，积极探索医疗AI应用场景，为医药创新赛道源源不断输送增长动能。 2025年7月31日，国务院常务会议审议通过《关于深入实施"人工智能+"行动的意见》，人工智能政策支 持导向进一步明确且强烈。AI+医疗细分应用广泛，其中AI病理诊断、AI影像及AI制药应用相对成熟， 或将加速兑现商业化价值。 对于投资者而言，持仓 ...

消息面上，京东健康收入持续超预期 ，AI赋能医疗健康生态闭环建设加速。 截至2025年8月15日 9:55，$港股医疗ETF（159366）$涨超2%，成分股京东健康（6618）涨超10%，为该ETF第二大成分股，占比超10%。 流动性方面，港股医疗ETF市场交投活跃。拉长时间看，截至8月14日，港股医疗ETF近1月日均成交2.92亿元。 | 序号 | 名称 | 代码 | 涨跌幅 ▼ | | --- | --- | --- | --- | | 1 | 京东健康 | 6618 | 10.21% | | 2 | 一脉阳光 | 2522 | 7.35% | | 3 | 平安好医生 | 1833 | 3.26% | | 4 | 美中嘉和 | 2453 | 3.58% | | 5 | 阿里健康 | 0241 | 3.35% | | 6 | 百济神州 | 6160 | 1.84% | | 7 | 信达生物 | 1801 | 1.72% | | 8 | 先健科技 | 1302 | 1.43% | | 9 | 微创机器人-B | 2252 | 1.18% | | 10 | 思派健康 | 0314 | 1.04% | 此外，在 ...

恒生医药ETF（159892）：聚焦创新药龙头企业； 医药板块近期持续吸引资本关注，红杉中国、上实资本等机构持续活跃。据医药魔方InvestGo数据库显 示，今年7月中国医疗健康一级市场迎来超125家机构出手，投资总金额达57.67亿元，较6月环比增幅超 52%，医疗板块已成为机构配置的重要方向。 细分领域中，创新药与医疗器械成为吸金主力。在集采反内卷、出海BD合作频发、CXO行业逐步复苏 及AI医疗加速兴起等多重利好因素提振下，创新药板块展现出强劲发展势头，市场关注度持续升温， 投资者对该领域的信心不断增强。多家机构分析认为，今年或将成为创新药行业发展的关键元年。 相关ETF： 港股通医疗ETF（520510）：CXO+AI医疗含量全市场领先。 每日经济新闻 ...

机构观点方面，中信建投指出，医疗器械行业拐点已至，关注业绩有望迎来拐点、国际化能力较强、中 长期增长逻辑较好的各细分赛道龙头，二季度或三季度有望业绩高增长或逐步迎来拐点的标的；短期业 绩承压，但长期增长稳健、26年有希望加速增长的公司；集采优化政策相关潜在业绩和估值修复；医疗 新科技方向如脑机接口、AI医疗、手术机器人、外骨骼机器人等。 长江证券湖南分公司首席分析师王振怀表示，昨天液冷服务器概念持续活跃，消息面上，根据浙商证券 测算，英伟达GPU，及云厂商自研ASIC芯片共同驱动液冷市场快速增长，2025至2027年液冷市场规模 大约分别为354亿元、716亿元、1082亿元，2027年有望突破千亿市场空间。另外，根据IDC（国际数据 公司）发布的数据，预计2025年至2029年，中国液冷服务器市场年复合增长率将达到约48%，2028年市 场规模将达到约162亿美元。中信证券表示，谷歌、Meta、微软、AWS等定制ASIC芯片及英伟达GPU的 AI服务器热设计功率密度提升，对液冷的需求明确。随着ASIC芯片及英伟达GB300的持续放量，液冷 渗透率将大幅提升，市场空间扩容。国内液冷企业在技术、产品质量、成本、 ...

6月以来，AI医疗相关事件重磅不断。 6月30日，上海瑞金医院携手华为开源了RuiPath病理模型中核心的视觉基础模型，该模型涵盖肺癌、结 直肠癌等7大高发癌种，覆盖中国每年90%的癌症新发病例。同时，瑞金医院还启动了RuiPath病理大模 型全球多中心计划，旨在推动医疗AI技术的国际合作与发展。 RuiPath病理模型发布于2月18日，基于华为DCSAI解决方案打造，此次开源内容包括核心视觉架构及多 癌种测试数据集，标志着我国在数字病理AI领域取得重要突破。该病理模型可帮助医生提升诊断效 率，由病理医生整理的常用问题测试中，RuiPath的回答准确率高达90%以上。 来源：发布会视频截图 一直以来，华为都在积极布局AI医疗。在今年3月，华为正式组建医疗卫生军团，重点构建AI辅助诊断 解决方案体系，推动医疗大模型在临床场景的应用。 AI医疗成为巨头必争之地 AI医疗能够提高诊断效率、优化治疗方案、提升医疗资源利用效率，满足人们对更好医疗服务的期 待。在此背景下，AI医疗已成为科技巨头的必争之地，6月以来，国内各大科技公司纷纷发布相关产 品。 6月30日，在紫荆智康与清华大学智能产业研究院主办的系统发布会上，紫 ...